Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to $13.6 million.

  • International Stem Cell's Gains from Investment Securities changed N/A to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year change of. This contributed to the annual value of $12.5 million for FY2024, which is 605.93% up from last year.
  • International Stem Cell's Gains from Investment Securities amounted to $13.6 million in Q3 2025.
  • Over the past 5 years, International Stem Cell's Gains from Investment Securities peaked at $13.6 million during Q2 2025, and registered a low of $5.4 million during Q1 2022.
  • For the 5-year period, International Stem Cell's Gains from Investment Securities averaged around $9.5 million, with its median value being $9.7 million (2023).
  • In the last 5 years, International Stem Cell's Gains from Investment Securities surged by 243688.36% in 2021 and then soared by 605.31% in 2025.
  • Quarter analysis of 5 years shows International Stem Cell's Gains from Investment Securities stood at $5.4 million in 2021, then increased by 26.07% to $6.9 million in 2022, then surged by 72.16% to $11.8 million in 2023, then grew by 6.06% to $12.5 million in 2024, then grew by 8.98% to $13.6 million in 2025.
  • Its last three reported values are $13.6 million in Q3 2025, $13.6 million for Q2 2025, and $12.5 million during Q1 2025.